Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00326326 · ClinicalTrials.gov registry record · Phase 2
Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT00326326 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 84 participants.
The verdict
NCT00326326, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes
Interventions
- DRUG CP-778,875
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00326326
The ClinicalTrials.gov registry entry for NCT00326326 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-778,875 is the first listed.
NCT00326326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00326326 about?
NCT00326326 is a clinical study titled "Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.". To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes
What is the current status of trial NCT00326326?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2006-07. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00326326?
The interventions under investigation include: CP-778,875 (DRUG).
Who is sponsoring clinical trial NCT00326326?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.